Background: The predictive role of human epidermal growth factor receptor 2 (HER2) to adjuvant anthracyclinebased chemotherapy remains controversial. Here, we investigated the association between HER2 status and pathological response in breast cancer patients who received neoadjuvant anthracycline-based regimens.
introduction
Neoadjuvant chemotherapy or primary chemotherapy is increasingly used for operable primary breast cancer. Many studies have shown that the efficacy of neoadjuvant chemotherapy in breast cancer is at least equal to adjuvant chemotherapy in terms of survival [1] [2] [3] . Furthermore, neoadjuvant chemotherapy provides an in vivo assessment of tumor response to a particular chemotherapy regimen and, hence, permits optimization of therapy for patients based on their response [4] .
Data from large randomized trails demonstrated that the achievement of pathological complete response (pCR) in the breast after completion of neoadjuvant chemotherapy is associated with favorable long-term outcomes, regardless of neoadjuvant chemotherapy regimens [1, 2, [5] [6] [7] .
The anthracycline-based regimens are known be highly active in the treatment of breast cancer and are most commonly used in neoadjuvant chemotherapy settings [2, [8] [9] [10] [11] . However, only a minority of patients may achieve a pCR when receiving such neoadjuvant regimens [4] . It is now recognized that a proportion of breast tumors may exhibit resistance to a chemotherapeutic agent when the drug is administrated [12] [13] [14] . Therefore, the goal of neoadjuvant chemotherapy is to select the right patients who will benefit from a certain types of regimens and to spare the patients from receiving an ineffective treatment.
Human epidermal growth factor receptor 2 (HER2), a member of the epidermal growth factor family, is overexpressed in $20%-25% of breast cancers and is associated with an unfavorable clinical outcome [15, 16] . However, the predictive role of HER2 to chemotherapy remains controversial [15, [17] [18] [19] . Most studies indicated that, in the absence of adjuvant trastuzumab, patients whose tumors overexpressed or amplificated HER2 benefit from anthracycline-based therapy in adjuvant settings [18, 20] . In contradiction with this notion, one recent study showed that patients with HER2-negative tumors derive a larger benefit from adjuvant anthracyclines than do patients with HER2-positive tumors [19] . To date, few studies with large sample sizes are available for investigating the association between HER2 status and pathological response in neoadjuvant settings [21, 22] . Therefore, in the current study, we analyzed data from 538 patients with operable primary breast cancer who received neoadjuvant anthracycline-based regimens. The aim of this study was to investigate whether there was an association between HER2 status and pathological response in the neoadjuvant chemotherapy regimens.
patients and methods

patient selection
Breast cancer was diagnosed by a core-needle biopsy using a 14-gauge needle; only patients diagnosed with invasive breast cancer by pathology received the neoadjuvant chemotherapy. From January 2000 to January 2009, 1913 primary breast cancer patients with stage I-III disease received neoadjuvant chemotherapy at the Breast Center, Peking University Cancer Hospital. Among them, 538 patients received four to eight cycles of neoadjuvant anthracycline-based regimens. Patients who received other neoadjuvant chemotherapy regimens or received anthracyclines, but the cycles were less than four cycles, and HER2-positive patients who received trastuzumab treatment in addition to the chemotherapy were excluded for this study. All patients gave the written consent. This study was approved by the Research and Ethical Committee of Peking University Cancer Hospital.
The clinical size of primary breast cancer was determined by ultrasound before the start of chemotherapy and intervals of each two cycles. Patients received either mastectomy or breast-conserving therapy after completion of neoadjuvant chemotherapy. Most patients received adjuvant chemotherapy after surgery either using the same regimens of neoadjuvant chemotherapy or receiving other types of regimens; patients with four lymph nodes metastases or receiving breast-conserving surgery received radiotherapy; and patients with estrogen-receptor (ER)-and/or progesterone-receptor (PgR)-positive tumor received tamoxifen (20 mg/ day) or arimitase inhibitors (i.e. anastrozole 1 mg/day or letrozole 2.5 mg/ day).
The pCR was defined as no invasive breast tumor cells in breast after completion of neoadjuvant chemotherapy [1, 7, 23] . ER, PgR, and HER2 status ER, PgR, and HER2 status were determined using the core-needle biopsy breast cancer tissue obtained before initiation of neoadjuvant chemotherapy. ER and PgR were assessed by immunohistochemical assay using an ER monoclonal antibody (clone: 1D5; DAKO, Carpinteria, CA; dilution 1 : 100) and PgR monoclonal antibody (clone: 1A6; Zymed, San
Francisco, CA; dilution 1 : 100), respectively. ER or PgR immunostaining was considered positive when ‡10% of tumor cells showed positive nuclear staining. HER2 status was determined by immunohistochemistry (IHC) and/or by fluorescence in situ hybridization (FISH) in core-biopsy breast cancer tissue. HER2 expression was determined by IHC assay as described previously using a HER2-specific antibody (clone CB-11; Zymed; dilution 1 : 100). HER2 staining was graded according to the standard scoring method: no staining or staining observed in <10% of tumor cells was given a score 0; faint/barely perceptible staining detected in ‡10% of tumor cells was scored as 1+; a moderate or strong complete staining observed in ‡10% of tumor cells was scored as 2+ or 3+, respectively. HER2 score was available for 495 patients of this cohort: 349 cases were score 0, 27 cases 1+, 18 cases 2+, and 101 cases 3+, respectively. A score of 0 and 1+ was considered negative, whereas 3+ was considered positive; 18 tumors with score 2+ were further evaluated by FISH using Vysis kit (Vysis, Inc., Downers Grove, IL) according to the manufactory instruction; HER2 was considered amplified when the ratio of HER2/CEP17 signals was ‡2.2. Sixteen of the 18 tumors exhibited HER2 gene amplification by FISH.
statistics analysis
The associations between HER2, clinicopathologic characteristics, and pathological response to neoadjuvant chemotherapy were determined using Pearson's v 2 test. Disease-free survival (DFS) was defined as the time from date of diagnosis to first recurrence (local or distant) or death from breast cancer without a recorded relapse. Survival curves were derived from Kaplan-Meier estimates, and the curves were compared by log-rank tests. A logistic regression model was applied to determine whether a factor was independent predictor of pCR in a multivariate analysis. All statistical tests were two-sided, and P values <0.05 were considered statistically significant. The statistical analyses were performed using SPSS 13.0 software (SPSS Inc., Chicago, IL).
results patient characteristics
Five hundred and thirty-eight operable primary breast cancer patients received neoadjuvant anthracycline-based regimens; patients characteristics are presented in Table 1 . About 23.9% of breast tumors achieved pCR after completion of neoadjuvant chemotherapy (Table 1) . HER2 results are available in 495 patients; 23.6% of patients exhibited a HER2-positive tumor (Table 1) . Follow-up data were available for all 538 patients; the median follow-up was 28 months (range 6-107 months) in this cohort; during this period, 55 patients experienced relapse (local or distant metastases) or died of the disease.
association between HER2 status and pathological response
In this cohort of 538 patients, age was not significantly associated with pathological response (Table 2) . Patients with small tumors were more likely to have a higher rate of pCR than those with large tumors ( Table 2) . As expected, patients with ER-or PgR-negative tumors had a higher pCR rate than did patients with ER-or PgR-positive tumors (ER: 29.0% versus 18.9%, P = 0.007; PgR: 29.6% versus 17.1%, P = 0.001, respectively), high-grade tumors were also more likely to respond to treatment than low-grade tumors (III versus I + II, pCR: 35.0% versus 20.5%, P = 0.006), and patients who received more than four cycles were more likely to achieve pCR Annals of Oncology original article than those who received four cycles (Table 2) . Patients with pCR in their tumors had a higher percentage of breastconserving therapy and lower lymph nodes involvement than did patients with non-pCR (Table 2) . However, patients with HER2-positive tumors were significantly less likely than those with HER2-negative tumor to respond to neoadjuvant anthracycline-based regimens; HER2-negative tumors exhibited a higher pCR rate than did HER2-positive tumors (25.7% versus 14.7%, P = 0.013; Table 2 ).
Patients with HER2-negative tumor (378 cases) were further stratified by ER and PgR status, i.e. HER22 and ER and/or PgR+ subgroup and triple-negative (HER22, ER2, and PgR2) subgroup; the pCR rate in the two subgroups was 20.1% and 38.0%, respectively. The higher pCR rate was found in triplenegative group; triple-negative breast cancers were more sensitive to anthracycline-based neoadjuvant chemotherapy; however, the pCR rate of HER22 and ER and/or PgR+ group was still higher than that of HER2+ group (20.1% versus 14.7%).
If the pCR was considered as both breast tumors and axillary lymph nodes, there was also a significant association between HER2 status and pCR, HER2-negative tumors showed a higher pCR rate than did HER2-positive tumors in this analysis (21.4% versus 12.8%, P = 0.049, data not shown).
Multivariant analysis revealed that HER2 was an independent predictor of pCR after adjusted for age (£50 versus >50 years), tumor size (£2 versus >2 cm), ER (negative versus positive), PgR (negative versus positive), chemotherapy cycles (four cycles versus more than four cycles), and tumor grade (III versus I + II) in this cohort of 538 patients (odds ratio = 3.14; 95% confidence interval = 1.60-6.16, P = 0.001; Table 3 ). Patients with HER2-negative tumors were three times more sensitive to neoadjuavnt anthracycline-based chemotherapy than those with HER2-positive tumors. Although the negative ER and PgR status, high tumor grade (III), and small tumor size (<2 cm) remained as an independent favorable predictor of pCR (Table 3) , negative HER2 status exhibited the strongest one. Figure 1 , P = 0.007); the expected 3-year DFS in the pCR group and the non-pCR group were 95.8% and 86.6%, respectively. We then analyzed the association between pCR and DFS according to the HER2 status. Patients who achieved a pCR in their tumors had a better DFS compared with those who did not achieve a pCR in both HER2-positive and -negative tumors; among patients with non-pCR in their tumors, patients with HER2-negative tumors had a better DFS than did patient with HER2-positive tumors (Figure 2 , P = 0.001).
discussion
In this respective study, we are first to show that patients with HER2-positive tumors are less likely to benefit from anthracycline-based chemotherapy compared with those with HER2-negative tumors in a neoadjuvant setting.
Adjuvant anthracycline-based chemotherapy has been shown to improve both DFS and overall survival rates in women with early-stage breast cancer, regardless of ER, PgR, and HER2 status [24] . Many studies suggested that HER2-positive tumors are more sensitive to adjuvant anthracycline-based chemotherapy than HER2-negative tumors [18, 20, 25, 26] . A recent meta-study based on a pool of eight randomized trials investigated the association between HER2 and the efficacy of anthracyclines compared with non-anthracycline-containing regimens and indicated that patients with HER2-positive tumors are more likely to benefit from anthracycline-based regimen in adjuvant settings [18] ; however, only two of these studies were sufficiently powered to show a statistical significance, while six were inconclusive or did not reach significance. In addition, Pegram et al. [27] investigated whether HER2 overexpression affected sensitivity to doxorubicin in four breast cancer cell lines that were transfected with the HER2 gene and then exposed to doxorubicin. In this in vitro study, HER2 overexpression did not confer increased sensitivity to doxorubicin. This finding argues the notion that HER2-positive tumors are more likely to respond to anthracyclines. It is suggested that HER2-positive tumor benefiting from anthracyclines is due to topoisomerase IIa amplification, as topoisomerase IIa is the target of anthracyclines [28] . However, a recent study indicated the topoisomerase IIa amplification is not associated with chemosensitivity in anthracyclines [17] . Bartlett et al. [19] recently also showed that patients with normal HER2 gain a larger benefit from epirubicin than do patients with HER2- Few studies with reasonable sample sizes are available for investigating HER2 status and response to neoadjuvant chemotherapy in the literature. Our present study, to our knowledge, is the largest one to investigate HER2 and response to neoadjuvant anthracycline-based chemotherapy, and we are able to determine HER2 status since we used 14-gauge core biopsy needle to obtain breast cancer tissues before neoadjuavnt chemotherapy. Neoadjuvant chemotherapy provides a unique platform to assess the efficacy of a chemotherapy regimen in vivo, and pCR is surrogate of efficacy for neoadjuvant chemotherapy. The association between pCR after neoadjuvant chemotherapy and favorable outcome is confirmed in many studies including the present one as well. In this study, we found that HER2-positive tumors had a lower pCR rate than did HER2-negative tumors, and HER2 status was an independent predictor of pCR after adjusted for age, ER, and PgR status, tumor size, chemotherapy cycles, and tumor grade in a multivariate analysis, with HER2-positive tumors being less likely to respond to anthracyclines. The predictive power of HER2 was stronger than ER and PgR status, tumor size, and tumor grade. Thus, our present findings provided direct evidence that patients with HER2-positive tumors did not benefit from anthracyclines in a neoadjuvant setting. In our recent study, 219 patients received two cycles of anthracyclines followed by four cycles of paclitaxel plus carboplatin regimen [29] ; we found HER2-positive tumors are more likely to respond to the paclitaxel-containing neoadjuvant chemotherapy (unpublished data).
The 23.9% pCR rate observed in the current study was higher than that in the findings of National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [23] . In B-27 two subgroup, women (arm I and arm III) only received four cycles of preoperative doxorubicin and cyclophosphamide (AC) regimen followed by surgery; the pCR rate in the two subgroups are 12.9% and 14.5%, respectively. The discrepancy between our study and B-27 may be due to several reasons. First, our regimens contained 5-fluorouracil, pirarubicin or epirubicin, and cyclophosphamide, and some patients received more than four cycles, while patients in B27 (arms I and III) received four cycles AC; second, higher percentage of small tumor was found in our cohort compared with B-27 (i.e. £2 cm tumor, 36.1% versus 13.5%-14.1%), small tumors are more likely to reach pCR in many studies; third, 47.7% of tumors in our cohort were ER negative; ER-negative tumors are more likely to respond to neoadjuvant anthracyclines-based chemotherapy than ER-positive tumors.
Patients achieved a pCR in their tumors after completion of chemotherapy was associated with better outcome irrespective of HER2 status; on the other hand, patients with HER2-positive tumors who did not achieve pCR had a worse outcome than did patients with HER2-negative tumors who did not achieve a pCR. Therefore, patients with HER2-positive tumors who did not achieve a pCR after completion of neoadjuvant anthracycline-based regimes may select other types of regimens (i.e. paclitaxel-containing regimens) or in combination with trastuzumab after surgery.
In this study, ER-or PgR-negative, small, and high-grade tumors had a higher pCR rate than did ER-or PgR-positive, large, and low-grade tumors. These observations were concordant with multiple previous studies in neoadjuvant settings [5, 30, 31] , indicating that ER-or PgR-negative, small, and high-grade tumors are more sensitive to neoadjuvant chemotherapy irrespective of treatment regimens.
Our present study suggested that women with HER2-negative breast cancers rather than HER2-positive tumors benefit from anthracyclines treatment. However, our findings should be interpreted with caution; further independent studies are warranted to confirm our present findings in neoadjuvant chemotherapy settings.
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